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Abstract
Background: Approximately half of hereditary breast cancers have mutations in either BRCA1 or BRCA2. BRCA1 is a
multifaceted tumor suppressor protein that has implications in processes such as cell cycle, transcription, DNA damage
response and chromatin remodeling. This multifunctional nature of BRCA1 is achieved by exerting its many effects through
modulation of transcription. Many cellular events are dictated by covalent modification of proteins, an important
mechanism in regulating protein and genome function; of which protein methylation is an important posttranslational
modification with activating or repressive effects.
Methods/Principal Findings: Here we demonstrate for the first time that BRCA1 is methylated both in breast cancer cell lines
and breast cancer tumor samples at arginine and lysine residues through immunoprecipitation and western blot analysis.
Arginine methylation by PRMT1 was observed in vitro and the region of BRCA1 504–802 shown to be highly methylated.
PRMT1wasdetectedincomplexwithBRCA1504–802throughinvitrobindingassaysandco-immunoprecipitatedwithBRCA1.
Inhibition of methylation resulted in decreased BRCA1 methylation and alteration of BRCA1 binding to promoters in vivo as
shown through chromatin immunoprecipitation assays. Knockdown of PRMT1 also resulted in increased BRCA1 binding to
particular promoters in vivo. Finally, following methylation inhibition, Sp1 was found to preferentially associate with hypo-
methylated BRCA1 and STAT1 was found to preferentially associate with hyper-methylated BRCA1.
Conclusions/Significance: These results suggest that methylation may influence either the ability of BRCA1 to bind to
specific promoters or protein-protein interactions which alters the recruitment of BRCA1 to these promoters. Thus, given
the importance of BRCA1 to genomic stability, methylation of BRCA1 may ultimately affect the tumor suppressor ability of
BRCA1.
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Introduction
BRCA1 is a tumor suppressor protein that has implications in
processes such as cell cycle, transcription, DNA damage response,
and chromatin remodeling. One way to explain the multifaceted
nature of BRCA1 is that it exerts its many effects through
modulating transcription of various factors. BRCA1 was first
implicated in transcription when the C-terminus (amino acid, aa,
1560–1863) fused to Gal4 was able to activate transcription [1],
with aa 1760–1863 being the minimal transactivation domain
(TAD). Within this TAD are two BRCA1 C-terminus (BRCT)
motifs that are found in a large family of proteins important for
DNA damage response, such as DNA ligase IV, p53BP1, and base
excision response scaffold protein XRCC1 [2]. Since that time,
numerous other findings have served to strengthen the connection
between transcription and BRCA1. For instance, BRCA1 is part
of the RNA polymerase II holoenzyme complex [3,4,5]. BRCA1
also interacts with multiple cofactors and transcription factors,
including CBP/p300, Sp1, STAT1, Estrogen Receptor and BRG1
[6,7]. Among the genes found to be transactivated by BRCA1 are
MDM2, BAX, p21/WAF1, p27/KIP1, and GADD45a with p21/
WAF1 and GADD45a transactivation being independent of p53
[8,9,10,11,12,13].
Proteins involved in transcription are often regulated through
posttranslational modifications (PTMs), such as acetylation and
methylation. Acetylation is broadly linked with activation, whereas
methylation can have either activating or repressing effects
depending on the amino acid that is modified and the nature of
the modification (mono-, di-, or tri-methylation). One well known
examples of this is the transcription factor p53, where K372
monomethylation and K370 dimethylation result in stabilization
and activation of p53 versus K370 and K382 monomethylation,
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known PTMs of BRCA1 include phosphorylation and ubiquiti-
nylation [7]. The phospho-BRCA1 predominates in S phase and
subsequently becomes dephosphorylated after M phase [7]. This
cell cycle dependent phosphorylation occurs in the absence of
DNA damage and is accomplished by multiple protein kinases
including cyclin A/cdk2, cyclin E/cdk2, cyclin D/cdk4, and
aurora-A [7]. In addition, BRCA1 is phosphorylated following
DNA damage by ATR and ATM kinases [7]. Although epigenetic
changes to the BRCA1 gene have been extensively researched at
the DNA-level, proteome research has focused on phosphorylation
of BRCA1 by DNA damage protein kinases, while little
information is known about the effects of other PTM events.
Protein methylation can occur on both lysine and arginine
residues. Arginine methylation is carried out by a family of protein
arginine methyltransferases (PRMT), which contains eleven family
members to date [15]. These enzymes utilize S-adenosyl
methionine (AdoMet) as a methyl donor [16], and can be further
subdivided into type I and type II enzymes. Type I enzymes form
monomethylarginine (MMA) and asymmetric dimethylarginine
(aDMA) and type II enzymes catalyze the formation of MMA and
symmetric dimethylarginine (sDMA) [17]. PRMT1, PRMT2,
PRMT3, PRMT4/CARM1, PRMT6, and PRMT8 are type I
enzymes; while PRMT5, PRMT7, and PRMT9 are type II
enzymes. PRMT1 is the most predominant methyltransferase in
mammalian cells [18] and is responsible for the majority of
arginine methylation, thus the vast majority of research has been
focused on this enzyme [19]. A number of PRMT1 substrates have
been identified including 53BP1, histone H4, MRE11, nucleolin,
RNA helicase A, SAM68, and ERa [20,21,22,23]. Arginine
methylation can regulate multiple cellular processes including
transcription [24,25,26,27,28,29], protein-protein interactions
[30], nuclear trafficking [31,32], transcriptional elongation, DNA
damage response [22], and cell cycle checkpoints [22]. Lysine
methylation occurs mainly through the SET domain family of
proteins. These enzymes were originally termed histone methyl-
transferases due to their ability to methylation various histone
protein residues [33], but in light of the identification of many
non-histone protein substrates they are now referred to as protein
lysine methyltransferases (PKMTs). The exception to this is the
DOT1 family of lysine methyltransferases. Lysine residues can be
mono-, di-, or tri-methylated [34,35].
Here we have identified for the first time the arginine and lysine
methylation of BRCA1 in tissue culture cell lines as well as breast
tumor tissue samples. We show that BRCA1 is methylated by
PRMT1 in vitro within the 504–802 region. PRMT1 was detected
in complex with BRCA1 504–802 through in vitro binding assays
and co-immunoprecipitated with BRCA1. Inhibition of methyla-
tion resulted in decreased BRCA1 methylation and alteration of
BRCA1 binding to promoters in vivo. Knockdown of PRMT1 also
resulted in increased BRCA1 binding to particular promoters in
vivo. Finally, following methylation inhibition, Sp1 was found to
preferentially associate with hypo-methylated BRCA1 and STAT1
was found to preferentially associate with hyper-methylated
BRCA1. These findings indicate that BRCA1 is posttranslationally
modified through methylation by PRMT1 and that this methyl-
ation influences its ability to bind to different promoters in vivo.
Results
BRCA1 is methylated in breast cancer cell lines
Methylation of proteins can have either activating or repressive
effects depending on the amino acid that is modified (arginine-R or
lysine-K) and whether it is mono-, di-, or tri-methylated [36]. For
example, K4 methylation on histone H3 is an indicator of actively
transcribed genes [36]. In contrast, methylation of histone H3K9,
H3K27, and H4K20 is involved in heterochromatin formation and
gene silencing [36]. To date there are no reports of BRCA1 protein
methylation. Based on the role of BRCA1 in transcription and the
influence of methylation on various transcription factors, we
speculated that BRCA1 may be methylated. In silico analysis
revealed a total of seven R and ten K residues in BRCA1 that could
potentially be methylated (Figure 1a). Interestingly, two of these
residues, R1076 and R1751 have known BRCA1 mutations,
R1076T, R1751Q and R1751P, according to the Breast Cancer
Information Core (http://research.nhgri.nih.gov/bic/). To deter-
mine if methylated BRCA1 could be detected in breast cancer cell
lines, two cell lines, MCF-7 and MDA-MB-231, were analyzed.
BRCA1 was immunoprecipitated and western blot analysis
performed with anti-K methyl, anti-R methyl and anti-BRCA1
antibodies. Results in Figure 1b indicated that BRCA1 is
methylated on both K and R residues in MDA-MB-231 cells, but
only R methylation could be detected in MCF-7 cells. These cell
lines have very distinct characteristics, with MDA-MB-231 being
triple negative and MCF-7 being ER and PR positive. In addition,
MDA-MB-231 is a highly metastatic cell line, whereas MCF-7 is
not. To demonstrate that the methyl band observed is specific to
BRCA1, BRCA1 was immunoprecipitated from MDA-MB-231
and UWB1.289 BRCA1 negative cells (Figure 1c). No methyl band
was detected in UWB1.289 cells, indicating that the methylated
band is specific to BRCA1. To further characterize BRCA1
methylation status, MDA-MB-231 cells were synchronized by
nocodazole treatment and cell populations collected at various
stages of the cell cycle. Results in Figure 1d indicate that R
methylation can be detected throughout the cell cycle with no
drastic changes, suggesting that this PTM may not be cell cycle
regulated. Synchronization was verified by western blotting for
cyclin B, cyclin D1, cyclin E (Figure 1e), with cdk4 and actin serving
as controls. Collectively, these results indicate that BRCA1 is
methylated in breast cancer cell lines. This is the first time to our
knowledge that BRCA1 has been shown to be methylated.
BRCA1 is methylated in ex vivo patient samples
To determine if BRCA1 is also methylated in ex vivo patient
samples, four different breast tumor tissue samples (BT1-4) were
tested. Interestingly, 3 of the 4 samples were triple negative breast
cancers (BT1, 3, and 4), which are extremely difficult to treat. BT3
was ER positive, PR negative and does not have HER-2
overexpression. We immunoprecipitated BRCA1 from BT1-4
and western blotted with anti-K methyl, anti-R methyl and anti-
BRCA1 antibodies (Figure 2a). Our results indicate that BRCA1 is
methylated at both K and R residues (lanes 1–4) in all four breast
tumor patient samples, while no methylation was observed with
the negative control IgG IP (lane 5). To investigate methylation
status in normal tissue, a matched tumor sample was equally
processed and immunoblotted with anti-R methyl antibody.
BRCA1 appears to be expressed and methylated in higher
amounts in the one normal tissue examined (Figure 2b, compare
lanes 2 and 3). Of interest, BRCA1 levels were not detected when
western blotting the non-immunoprecipiated material, indicating
that these tissues samples express very low levels of BRCA1.
Tumor samples 11559-1 is an ER positive, PR negative, non-
overexpressed HER-2 invasive ductal carcinoma, similar to BT2
in panel 2a. Larger sample sizes are necessary to determine if
BRCA1 methylation occurs more frequently in particular types of
breast cancer or in normal breast tissue. These preliminary results
demonstrate that both K- and R-methylation are detected in
normal and breast tumor tissue samples.
BRCA1 Methylation
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Results above indicate that BRCA1 protein is methylated in both
cancer cell lines and patient samples. We were interested in the site
of BRCA1 arginine methylation and for that purpose, GST-
BRCA1 constructs spanning BRCA1 protein were used for in vitro
methyltransferase assays. Due to the lack of a previously identified
enzyme, GST-PRMT1 was chosen for this analysis because
PRMT1 is responsible for approximately 85% of all arginine
methylation [19]. GST-BRCA1 constructs spanning the entire
protein (Figure 3a) were incubated in a reaction mixture containing
GST-PRMT1 enzyme, buffer, and S-Adenosyl-L [methyl-3H]
methionine as a source of radio-labeled methyl groups. Core
histones were used as a positive control, as PRMT1 has been shown
to methylate histone H4 [17,37] and GST was used as negative
control. BRCA1 fragment 504–802 was consistently the most highly
methylated in repeated experiments, while no methylation was
detected for GST-BRCA1 1501–1861(Figure 3a). Lower levels of
methylation were observed with BRCA1 1–500, 452–1079, and
1021–1552. As BRCA1 504–802 overlaps with GST-BRCA1 697–
1276,which exhibitedno methylation, amino acids 504–696 arethe
minimal area necessary for the observed methylation. According to
the predicted methylation sites in Figure 3a, the only arginine
predicted to be methylated within the 504–802 region is R610
(highlighted in red in Figure 3b). R610 is not the typical GAR motif
present in many PRMT1 substrates, but is an RXR sequence,
which is methylated in Poly(A)-binding protein II (PABPII) by
PRMT1 [38]. Therefore, it is possible that other arginine residues
within BRCA1 504–802 are methylated (highlighted in blue in
Figure 3b).
As BRCA1 is a poorly conserved protein, we were interested to
determine if the predicted methylation site was a conserved residue.
Full length BRCA1 sequences from human, four non-human
primates and two rodents were aligned using Clustal W in order to
analyze conservation of the predicted site within our identified
Figure 1. BRCA1 is methylated at both arginine and lysine residues in breast cancer cell lines. (a) Predicted BRCA1 methylation sites
generated by Memo: Methylation Modification Prediction Server (http://www.bioinfo.tsinghua.edu.cn/,tigerchen/memo.html) R=Arginine and
K=Lysine. (b) Two milligram of whole cell protein extracts from MCF-7 and MDA-MB-231 cells were immunoprecipitated with either BRCA1(C-20) or
rabbit normal IgG antibody, separated on a 4–20% gel by SDS-PAGE, and western blotted with antibodies against K-methyl, R-methyl and BRCA1(C-
20). Input represents 1/10 of immunoprecipitated material. Results are representative of three independent experiments. (c) One milligram of whole
cell protein extracts from MDA-MB-231 and BRCA1-null UWB1.289 cells were immunoprecipitated with either BRCA1(C-20) or rabbit normal IgG
antibody, separated on a 4–20% gel by SDS-PAGE, and western blotted with antibodies against R-methyl and BRCA1(C-20) in order to validate
observed methylated bands. Densitometry of R-methylation was normalized to amount of detected immunoprecpipitated BRCA1, background
subtracted based on IgG counts. (d) One milligram of whole cell protein extracts from synchronized MDA-MB-231 cells were immunoprecipitated
with either BRCA1(C-20) or rabbit normal IgG antibody, separated on a 4–20% gel by SDS-PAGE, and western blotted with antibodies against R-
methyl and BRCA1(C-20). Densitometry of R-methylation was normalized to amount of detected immunoprecpipitated BRCA1, background
subtracted based on IgG counts. Input represents 1/10 of immunoprecipitated material. (e) Whole cell protein extracts from synchronized MDA-MB-
231 cells were separated on a 4–20% gel by SDS-PAGE, and western blotted with antibodies against Cyclin B(H-433), Cyclin D1(M-20), Cyclin E(C-19),
cdk4(H-303) and actin(C-11).
doi:10.1371/journal.pone.0011379.g001
BRCA1 Methylation
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ation site and flanking residues of human BRCA1
600IHNS-
KAPKKNRLRRKSSTRH
619 are highly conserved in all sequenc-
es analyzed, even in rodent BRCA1 sequences which presented
approximately 55 percent identity to human BRCA1 (Figure 3c).
To confirm an interaction between PRMT1 and BRCA1, all
the GST-BRCA1 constructs utilized for the methyltransferase
assay were used for a pull-down assay with total cell lysates from
HeLa cells. HeLa cells were chosen as they display high levels of
PRMT1 expression in contrast to other breast cancer cell lines
(data not shown). An anti-PRMT1 western blot of the GST pull-
down revealed that the only detectable interaction between
PRMT1 and BRCA1 was occurring at the previously identified
region of 504–802 (Figure 3d). To further corroborate this
interaction, whole cell extracts were prepared and immunopre-
cipitated with BRCA1 or IgG and western blotted with anti-
PRMT1. BRCA1-PRMT1 interaction was observed specifically
with the BRCA1 immunoprecipitation and not with the IgG
(Figure 3e). Collectively, these results indicate that PRMT1
methylates BRCA1 in vitro, that the region of 504–802 is
methylated, and that physical interaction of PRMT1-BRCA1 is
only detectable at the 504–802 region of BRCA1.
Methylation of BRCA1 alters promoter binding in vivo
The internal region of BRCA1 (aa 452–1079) contains two DNA
binding domains, DB1 at aa 498–663 and DB2 at aa 936–1057 [39].
BRCA1 binds to branched DNA structures [40] as well as the
TTC(G/T)GTTG consensus sequence [41]. Therefore, it can
influence DNA damage repair pathways such as homologous
recombination as well as being a transcriptional cofactor. We have
previously shown that BRCA1 can bind to eight novel promoters
containing the TTC(G/T)GTTG consensus site [42] and wondered
whether methylation of BRCA1 influences the binding of BRCA1 to
these promoters. To this end, MDA-MB-231 cells were treated with
the methyltransferase inhibitor adenosine dialdehyde (AdOx) [43].
AdOx treatment resulted in decreased BRCA1 arginine methylation
(Figure 4a), further verifying that BRCA1 is methylated and providing
a system to test the influence of methylation on the function of BRCA1.
ChIP assays from untreated and AdOx treated cells were performed
using antibodies against histone H3-pS10 (positive control), IgG
(negative control) and BRCA1. Interestingly, BRCA1 binding was
increased at the AP endonuclease (APEX), Ras homolog gene family
member G (ARHG) and the growth arrest and DNA damage
inducible family member G (GADD45G) when BRCA1 is hypo-
methylated (Figure 4b). Conversely, estrogen receptor beta (ESR2), G-
Figure 2. Methylation of BRCA1 in ex vivo breast tumor samples. (a) Solid breast tumor tissue was ground with a mortar and pestle in the
presence of liquid nitrogen to create a powdered tissue. RIPA buffer was added to the powdered tissue, the sample vortexed for 60 seconds, and
placed on ice for 45 minutes. Samples were homogenized with a syringe and needle, followed by centrifugation at 14,000 g for 10 minutes. Two
milligram of whole cell protein extracts from four different breast tumor samples (BT1-4) were immunoprecipitated with either BRCA1(C-20) or rabbit
normal IgG antibody, separated on a 4–20% gel by SDS-PAGE, and western blotted with an anti-K methyl, anti-R methyl and anti-BRCA1 antibodies.
Results are representative of two independent experiments. Characteristics of tumor tissues are as follows: BT1: infiltrating ductal carcinoma, age 55,
African American, ER negative, PR negative, HER2 negative, p53 negative. BT2: infiltrating lobular carcinoma, age 83, Caucasian, ER positive, PR
negative, HER2 negative, p53 negative. BT3: variant papillary serous type of ductal carcinoma, age 54, African American, ER negative, PR negative,
HER2 negative, p53 negative. BT4: infiltrating ductal carcinoma, age 68, Caucasian, ER negative, PR negative, HER2 negative, p53 positive. (b) Matched
breast tumor tissue was processed as described. Four milligram of whole cell protein extract were immunoprecipitated with either BRCA1(C-20) or
rabbit normal IgG antibody, separated on a 4–20% gel by SDS-PAGE, and western blotted with an anti-R methyl and anti-BRCA1 antibodies. Input
represents 1/5 of immunoprecipitated material.
doi:10.1371/journal.pone.0011379.g002
BRCA1 Methylation
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11379BRCA1 Methylation
PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11379protein coupled receptor 85 (SREB2) and the mesothelial fibroblast
growth factor 9 (FGF9) exhibited a marked decrease of BRCA1
binding upon protein methylation inhibition. Lastly, the RING1 and
YY1 binding protein (RYBP) promoter, somatostatin (SST) and the
estrogen regulated gene, pS2 displayed no change in promoter binding
between BRCA1 methylation states (Figure 4b). These results indicate
that methylation of BRCA1 could play an important role in BRCA1
DNA binding at specific promoters in vivo.
Decreased levels of PRMT1 alters BRCA1 promoter
binding in vivo
To further characterize the specific impact of BRCA1
methylation by PRMT1, PRMT1 cellular levels were decreased
by means of RNAi. A titration of PRMT1 siRNA indicated that at
50 nM, PRMT1 protein levels were decreased by 90% (Figure 5a).
Therefore, 50 nM PRMT1 siRNA was utilized for ChIP assays to
determine the influence of PRMT1 on BRCA1 DNA binding.
Consistent with ChIP results from the AdOx treated cells, PRMT1
knockdown resulted in a dramatic increase of BRCA1 DNA
binding to the APEX and GADD45G promoters (Figure 5b, lanes
7–8). A modest increase in binding was also observed at the
ARHG gene. ORC4L was used as an internal control for no
known interaction with BRCA1 [42]. No change in H3-pS10 was
observed following PRMT1 knockdown. These results further
suggest that PRMT1 methylates BRCA1 and that its capacity to
methylate affects binding of BRCA1 to its responsive promoters.
Figure 3. PRMT1 methylates and associates with BRCA1. (a) GST-BRCA1 constructs (0.5 mg) and core histones (1 mg) were incubated with
purified recombinant PRMT1 enzyme (0.2 mg) in the presence of 0.55 mCi SAdenosyl- L-[methyl-3H] methionine. GST was used as negative control and
all GST-BRCA1 construct methylation levels normalized to background GST methylation levels. An average result of two independent experiments
run in triplicates is shown. (b) The amino acid sequence of BRCA1 504–802 with arginine (R) residues within the 540–696 minimal region highlighted
in blue and bolded, and the predicted methylated arginine residue highlighted in red, underlined and bolded. (c) Multiple sequence alignment
generated by Clustal W of four non-human primates and two rodent BRCA1 full length sequences. Score represents pairwise alignment against full
length human BRCA1. Amino acid residues are color-coded according to physical properties: basic (magenta), small hydrophobic (red) and hydroxyl +
amine + basic (green). Consensus symbols for degree of conservation observed is represented by ‘‘*’’ (residues in column are identical in all seven
sequences), ‘‘:’’ (conserved substitutions observed), and ‘‘.’’ (semi-conserved substitutions observed). (d) Two milligram of HeLa whole cell protein
extract was incubated with 0.5 mg GST-BRCA1 constructs, beads were washed twice with TNE150 + 0.1% NP-40 and once with TNE50 + 0.1% NP-40,
separated on a 4–20% gel by SDS-PAGE, and probed with an antibody against PRMT1. Input represents 1/10 of immunoprecipitated material. (e) Two
milligram of HeLa whole cell protein extract were immunoprecipitated with anti-BRCA1 and anti-IgG antibodies, beads were washed twice with
TNE150 + 0.1% NP-40 and once with TNE50 + 0.1% NP-40, separated on a 4–20% by SDS-PAGE, and probed with an anti-PRMT1 antibody. Input
represents 1/10 of immunoprecipitated material. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0011379.g003
Figure 4. Methylation status of BRCA1 alters BRCA1-DNA interactions at specific promoters in vivo. (a) MDA-MB-231 cells were treated
with AdOx (30 mM) in order to observe BRCA1 methylation inhibition upon treatment. Two milligram of MDA-MB-231 whole cell protein extract was
immunoprecipitated with anti-BRCA1 and anti-IgG antibodies, separated on a 4–20% gel by SDS-PAGE, and probed with anti-K methyl antibody. Blot
was stripped and reprobed with anti-BRCA1 antibody. Input represents 1/10 of immunoprecipitated material. Results are representative of two
independent experiments. (b) MDA-MB-231 cells were treated with AdOx (30 mM) for 48 hours prior to being collected for ChIP analysis. Antibodies
used for ChIP were anti-BRCA1 (10 mg), anti-IgG (10 mg), and anti-histone H3-phosphorylated at S10 (H3-pS10, 5 mg). PCR products were run on a 2%
agarose gel and visualized with ethidium bromide staining. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0011379.g004
BRCA1 Methylation
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BRCA1 is known to participate in many protein-protein
interactions. A schematic diagram of the BRCA1 504–802 protein
region is displayed in Figure 6a to indicate protein-protein
interactions that have been reported within the region and thus
interactions that may be affected by the methylation status of
BRCA1. These include transcriptional coactivator BRG1 [44],
DNA repair protein RAD50 [45], regulators of nuclear BRCA1
transport importin-a and BRAP2 [46,47], centrosome and
microtubule component c-tubulin [48], and transcription factors
Sp1 and STAT1 [49,50]. To investigate whether hyper- or hypo-
methylation status of BRCA1 interfered with protein-protein
interactions, AdOx treated MDA-MB-231 whole cell protein
extracts were immunoprecipitated with anti-BRCA1 or anti-IgG
antibodies. Immunoblotting of electrophoresed proteins revealed
Sp1 preferentially bound to hypo-methylated BRCA1 (Figure 6b,
compare lanes 1 and 2). To determine if AdOx has an effect in the
abundance of Sp1 (as observed in Figure 6b, lanes 5 and 6), MDA-
MB-231 cells were subjected to AdOx treatment and immuno-
blotted with anti-Sp1 (Figure 6c). Densitometry from three
independent experiments indicates that Sp1 total levels tend to
decrease in AdOx treated cells, highlighting the relevance of
observed increase in BRCA1-Sp1 interaction in Figure 6b lanes 1
and 2. In contrast, we observed STAT1 preferentially associated
with hyper-methylated BRCA1 (data not shown). These results
suggest that methylation of BRCA1 affects protein-protein
interactions.
Discussion
The molecular function of BRCA1 has been subject of focused
studies since it was cloned in 1994 [51]. Extensive studies have
characterized BRCA1 as a multifaceted tumor suppressor protein
due to its role in cell cycle progression, DNA repair and DNA
damage response processes, transcriptional pathway regulation
and apoptosis [7]. BRCA1 is regulated through phosphorylation
Figure 5. Decreased levels of PRMT1 alters BRCA1 promoter binding in vivo. (a) HeLa cells were transfected with different concentrations of
PRMT1 siRNA (10, 25, 50 nM) following manufacturer’s instructions. Results are representative of two independent experiments. (b) HeLa cells
transfected with 50 nM Luc or PRMT1 siRNA were collected for ChIP analysis. Anti-BRCA1 (10 mg), anti-IgG (10 mg), and anti-histone H3-
phosphorylated at S10 (H3-pS10, 5 mg) antibodies were used for ChIP analysis. PCR products were run on a 2% agarose gel and visualized with
ethidium bromide staining. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0011379.g005
BRCA1 Methylation
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ATR, following DNA damage produced by ionizing radiation,
UV, or DNA damaging inducing chemicals such as mitomycin C
[52,53,54,55,56]. Our in vitro and in vivo analyses indicate another
avenue for BRCA1 regulation through arginine methylation, and
PRMT1 as a cellular arginine methyltransferase candidate for this
methylation. Interestingly, methylation of BRCA1 by PRMT1
indicates a regulatory mechanism for BRCA1 binding to
particular promoters as well as protein-protein interactions.
We have demonstrated that BRCA1 is methylated both in
breast cancer cell lines and breast cancer tumor samples. Both
arginine and lysine methylation was detected. Interestingly, lysine
methylation was only detected in MDA-MB-231 cells but not
MCF-7, while arginine methylation was detected in both. Both cell
lines were obtained from pleural effusions, but differ in their
characteristics. In vitro, MDA-MB-231 cells display a highly
invasive phenotype in contrast to MCF-7 cells, while they both
have the ability to form in vivo tumors in mice [57,58]. In
correlation with breast cancer, MDA-MB-231 cells are triple
negative and posses a mutant p53. MCF-7 cells are double
positive, negative for HER2 and posses wild-type p53 [58,59,60].
It is tempting to speculate that methylation patterns for both lysine
and arginine may be linked to phenotypical characterization of
breast cancer types. However, a much larger sample size is needed
to draw a clear conclusion in this regard. Arginine methylation by
PRMT1 was observed in vitro and the region of BRCA1 504–802
was highly methylated. One well known PRMT consensus
methylation sequence is the arginine and glycine-rich (GAR)
motif (i.e. repeating RGG sequences), which is recognized by
PRMT1, 3, 5, 6, and 8 [61]. However, more recently a focused
peptide library screen was used to identify additional sequences
methylated by PRMT1 [62]. The authors demonstrated that
additional sequences such as ‘‘RLG’’, ‘‘RYG’’, ‘‘RFG’’, ‘‘RTG’’,
and ‘‘RKG’’ were substrates for PRMT1. In addition, other
PRMTs, such as PRMT4 have no known consensus site, which
hinders the identity of arginine methylated proteins. The predicted
methylation site at residue 610 harbors a ‘‘RXR’’ sequence, where
X is occupied by a leucine, making it the most likely candidate for
methylation within that area.
Upon methylation inhibition, in vivo BRCA1 binding to the
APEX, ARHG and GADD45G promoters was increased. BRCA1
binding to the ESR2, SREB and FGF9 gene promoters was
hindered. In addition, BRCA1 binding to RYBP, SST and pS2
gene promoters was unaffected. These results suggest that
methylation may influence either the ability of BRCA1 to bind
to specific promoter or protein-protein interactions which alters
the recruitment of BRCA1 to these promoters. As can be observed
in Figure 4a, AdOx treatment abolished detectable levels of
Figure 6. BRCA1 methylation status alters protein-protein interactions at the 504-802 region. (a) Schematic of BRCA1 504-802 primary
sequence depicting important protein-protein interactions and domains that could be affected by the methylation of this region. (b) MDA-MB-231
cells were treated with AdOx (30 mM) in order to observe BRCA1 methylation inhibition upon treatment. Two milligram of MDA-MB-231 whole cell
protein extract was immunoprecipitated with anti-BRCA1 or anti-IgG antibodies, separated on a 4-20% gel by SDS-PAGE, and western blotted using
antibodies against Sp1 and BRCA1 proteins. Input represents 1/10 of immunoprecipitated material. Results are representative of two independent
experiments. (c) MDA-MB-231 cells were treated with AdOx (30 mM) and whole cell extract separated on a 4-20% gel by SDS-PAGE, and probed with
anti-Sp1 antibody. Densitometry was averaged from three independent immunoblots.
doi:10.1371/journal.pone.0011379.g006
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cellular methyltransferases, thus its effect regarding PRMT1 is
non-specific. However, BRCA1-DNA interaction at the APEX,
ARHG and GADD45G promoters upon siRNA-mediated
knockdown of PRMT1 mimicked the results observed when cells
were treated with the methyltransferase inhibitor. The difference
between the levels of increased binding observed in AdOx-treated
versus PRMT1 knockout samples may be due to compensatory
mechanisms by other PRMTs or lysine methylation. Preliminary
studies demonstrated that SETDB1, a PKMT member of the
SUV39 family of SET-domain containing proteins, methylated
BRCA1 in vitro (data not shown). Neither the site of methylation
nor the influence of lysine methylation on BRCA1 is known, but
will be the focus of future studies.
Protein-protein interactions at the BRCA1 504–802 region
involve several proteins that are important for transcription
pathways and in particular, protein localization. These include
BRAP2, importin-a, BRG1, Sp1, STAT1 and c-tubulin. BRCA1
localization also plays an important role in protein function, with
both cytoplasmic and nuclear targets. Subsequently, BRCA1 has
been found to posses two nuclear localizations signals (NLS) as well
as one nuclear export sequence (NES) that guide the shuttling
process of BRCA1 [63,64,65]. Albeit, mechanisms for this
shuttling process are not clearly understood. Interestingly, both
NLS are located in the vicinity of the identified BRCA1 region
that is being methylated. Specifically, NSL1 is located at residues
501–507 and NSL2 at residues 606–615. Furthermore, phosphor-
ylation of T508 at the Akt concensus phosphorylation motif
immediately adjacent NSL1 resulted in cytoplasmic accumulation
of BRCA1 [66], suggesting that methylation of this region may
possess similar shuttling regulatory mechanisms. PRMT1 is also
regulated through nucleo-cytoplasmic shuttling [67,68]. Impor-
tantly, enzymatic activity is required for this shuttling process
where a catalytically inactive mutant of PRMT1, rapidly
accumulates in the nucleus. The nuclear export of PRMT1 is
dependent on the release of the enzyme from its substrates
following methylation [67]. These findings suggest a dynamic
mechanism for the regulation of substrate methylation that is
dependent on the methylation status of its substrates, in this case,
BRCA1.
Upon hypomethylation of BRCA1, increased binding to Sp1
protein was observed. The Sp1 transcription factor is a potent
transactivator of the insulin-like growth factor-I receptor (IGF-I-R)
gene. Initially, the functional interaction between BRCA1 and Sp1
was suggested to regulate the IGF-I-R, a receptor overexpressed in
most breast cancers that serves as an antiapoptotic factor [69,70].
Later, the same group showed that BRCA1 itself does not exhibit
any specific binding to the IGF-I-R promoter but instead, it
prevented Sp1 binding the promoter by BRCA1-Sp1 interaction
at the BRCA1 260–802 region [50]. Moreover, it has been found
that BRCA1 gene expression is regulated by the IGF-I signaling
pathway where IGF-I enhances BRCA1 promoter activity and
that Sp1 is directly involved in BRCA1 gene transactivation [71].
Thus, it is possible that the status of BRCA1 methylation plays a
role in the transcriptional regulation of the IGF-I-R gene by
BRCA1 and Sp1. Because BRCA1 has an inhibitory control of the
IGF-I-R promoter as well as repressing the Sp1-induced
transactivation of the IGF-I-R gene, this suggests that methylated
BRCA1 state (as observed in our cancer cell lines and breast tumor
tissues) allows for decreased BRCA1-Sp1 binding which could be
part of a regulatory mechanism of the IGF-I-R gene expression.
The in vivo interaction of Sp1 with the IGF-I-R promoter in MDA-
MB-231 cells treated or untreated with AdOx still needs to be
characterized. We have however, observed decreased BRCA1
binding at APEX promoter, which is regulated by Sp1. APEX
participates in base excision repair through the recognition and
the initial step toward removing abasic sites [72]. The APEX
promoter contains Sp1 binding sites both upstream and down-
stream of the transcriptional start site [73,74,75]. Sp1 binding to
the downstream site regulates the expression of APEX in a cell
cycle dependent fashion [75]. Interestingly, our results indicate
that hypomethylated BRCA1 binds to the APEX promoter and
that this form of BRCA1 has increased binding to Sp1. Therefore
it is possible that BRCA1 is acting as a transcriptional coactivator
for Sp1 mediated APEX transcription. The precise role of BRCA1
in APEX transcription will be the focus of future studies.
In our current study we have identified a novel posttranslational
modification of BRCA1, namely methylation. We have only begun
to elucidate the role of arginine methylation in terms of regulating
BRCA1 protein-protein interactions and its transcriptional
coactivator function. Future studies will be focused on the
identification of the methylated residues, study of lysine methyl-
ation, and determining if there is a correlation between BRCA1
methylation and tumor progression. As was the case for BRCA1
phosphorylation, this study is the beginning and multiple future
research efforts are needed to uncover the intricate workings of
BRCA1 methylation.
Materials and Methods
Ethics Statement
The breast tumor samples were previously collected frozen
additional extraneous tissue that resulted following testing of breast
cancer samples for the presence of hormone receptors. Samples
were collected between 1985 and 1995 for pathologic examination
and diagnosis. Existing discarded tissue samples were stripped of
all identifying information. Ethical approval for the study was
given by the George Washington University IRB Committee
based on Federal Regulation 45 CFR 46.101(b) (4). The IRB
committee review indicated that informed consent was not
required as this was additional tissue left over from routine
pathological examination.
In silico BRCA1 analysis
Predicted methylation sites from the full length primary amino
acid sequence of BRCA1 were generated by the freeware MeMo:
Methylation Modification Prediction Server (http://www.bioinfo.
tsinghua.edu.cn/,tigerchen/memo.html).
Sequence analysis was performed using the Clustal W multiple
sequence alignment program [76]. Pan troglodytes (NCBI
AAR04849), Macaca mulatta (NCBI AAT44833), Pongo pygmaeus
(NCBI AAT44834), Gorilla gorilla (NCBI AAT44835), Mus musculus
(NCBI AAD00168) and Rattus norvegicus (NCBI AAC36493)
sequences were compared to human full length BRCA1 (NCBI
NP_009225).
Cell culture and breast tumor tissue samples
MDA-MD-231 and MCF-7 are epithelial breast carcinoma cells
derived from pleural effusions [59]. HeLa is a cervical carcinoma
cell line commercially available from the ATCC. All cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with
10% FBS, 1% L-glutamine, and 1% streptomycin/penicillin. All
cells were incubated at 37uC and 5% CO2. Cells were cultured to
confluency, washed and pelleted at 4uC for 15 minutes at
3,000 rpm. Pellets were lysed in a buffer containing Tris-HCl
pH 7.5, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF,
0.2 mM Na3VO4, 1 mM DTT and one tablet complete protease
inhibitor cocktail per 50 ml. Lysis was performed under ice-cold
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minutes at 14,000 rpm. Supernatant was transferred to a new tube
and protein was quantitated with Bradford protein assay (BioRad,
Hercules, CA, USA). For the breast tumor tissue lysis, the tissue
was ground with a mortar and pestle in the presence of liquid
nitrogen to create a powdered tissue. RIPA buffer (50 mM Tris-
HCl pH 7.5, 105 mM NaCl, 1% NP-40, 1% sodium deoxycho-
late, 0.1% SDS, 2 mM EDTA) was added to the powdered tissue,
the sample vortexed for 60 seconds, and placed on ice for 45
minutes. Samples were homogenized with a syringe and needle,
followed by centrifugation at 14,000 g for 10 minutes. Superna-
tants containing the lysate were quantitated with Bradford protein
assay (BioRad).
Cell Synchronization
MDA-MB-231 cells were synchronized by treatment with
nocodazole(200 ng/ml)for24 hours.Followingtreatment,arrested
cells were collected by the mitotic shake method. Adherent cells
were not collected. One fourth of the cells were collected (M phase
population) and the remaining cells were released in Dulbecco’s
modified Eagle’s medium supplemented with 20% FBS, 1% L-
glutamine, and 1% streptomycin/penicillin. Cells were collected at
4 hours (G1 phase), 12 hours (S phase), and 20 hours (G2/M
phase). Whole cell protein extracts from synchronized MDA-MB-
231 cells were separated on a 4–20% gel by SDS-PAGE, and
western blotted with antibodies against Cyclin B(H-433), Cyclin
D1(M-20), Cyclin E(C-19), cdk4(H-303) and actin(C-11).
Western blot analysis
Cell extracts were resolved by SDS PAGE on a 4–20% tris-
glycine gel (Invitrogen, Carlsbad, CA, USA). Proteins were
transferred to polyvinylidene difluoride microporous membranes
using the iBlot dry blotting system as described by the
manufacturer (Invitrogen). Membranes were blocked with Dul-
becco’s phosphate-buffered saline (PBS) 0.1% Tween-20+3%
BSA. Primary antibody against specified proteins was incubated
with the membrane in blocking solution overnight at 4uC. Western
blots were performed with a 1:1 of anti-dimethyl arginine (7E6)
(Novus, Littleton, CO, USA) and anti-methyl mono/di arginine
(AbCam, Cambridge, MA, USA), anti-methyl lysine (AbCam),
anti-PRMT1 (Cell Signaling, Danvers, MA, USA) and anti-
BRCA1(C-20), anti-Sp1(16C) and anti-STAT1 (E-23) (Santa
Cruz, Santa Cruz, CA) antibodies. Membranes were washed
twice with PBS+0.1% Tween-20 and incubated with HRP-
conjugated secondary antibody for one hour in blocking solution.
Presence of secondary antibody was detected by SuperSignal West
Dura Extended Duration Substrate (Pierce, Rockford, IL, USA).
Luminescence was visualized on a Kodak 1D image station.
Immunoprecipitation assay
For immunoprecipitation (IP) 1–4 mg of whole cell protein or
tumor tissue extracts were brought up to a final volume of 500 ml
withlysisbuffer and preclearedfor30minuteswith50 mlof30 %A/
G agarose bead slurry (CalBioChem, La Jolla, CA). Supernatants
were transferred to a new tube with 10 mg of BRCA1 or normal
rabbit IgG antibodies (Santa Cruz), and the solution was rotated
overnight at 4uC. The next day complexes were precipitated with
A/G beads for 90 minutes. Beads were washed twice with
TNE150+0.1% NP-40 and once with TNE50+0.1% NP-40.
GST pull-down and in vitro methyltransferase assay
GST tagged proteins were purified as described previously [53].
Constructs were washed three times with PBS+1% Triton X-100,
pelleted and resuspended in the methyltransferase buffer reaction.
Five hundred nanograms of GST-BRCA1 1–500, 452–1079, 504–
802, 697–1276, 1021–1552, 1501–1861 and core histones were
incubated with 0.2 mg of recombinant purified PRMT1 (Active
Motif, Carlsbad, CA, USA) in the presence of 0.55 mCi S-
Adenosyl-L-[methyl-
3H] methionine (GE Healthcare, Piscataway,
NJ, USA) and reaction buffer (50 mM Tris-HCl pH 8.0, 20 mM
KCl, 10 mM MgCl2, 250 mM sucrose, 10 mM b-mercaptoetha-
nol) overnight at 37uC in a final reaction volume of 20 ml. The
overnight methylation reactions (beads containing substrate) were
spun, washed three times in excess cold 10% TCA, 1% sodium
phosphate followed by once with 100% ethanol. Control samples
were spotted on GF/C membranes (Millipore, Bedford, MA,
USA), allowed to dry and processed equally as beads alone. Both
beads and filters were counted in Beckman Coulter LS6001C
scintillation counter in 2 ml of scintillation fluid (Beckman
Coulter, Fullerton, CA, USA). For the protein GST-BRCA1
pull-down, 2 mg of HeLa whole cell protein extract were brought
up to a final volume of 500 ml with lysis buffer and 500 ng of
GST-BRCA1 constructs were rotated at 4uC overnight. Beads
were washed twice with TNE150 + 0.1% NP-40 and once with
TNE50 + 0.1% NP-40.
siRNA-mediated knockdown of PRMT1 in HeLa cells
HeLa cells (1.8610
7 cells) were transfected with double-
stranded duplex with Hs_HRMT1L2_7 HP Validated siRNA
(Qiagen, Valencia, CA, USA) or luciferase (Dharmacon, Lafay-
ette, CO, USA) using Lipofectamine reagent according to the
manufacturer’s recommendations (Invitrogen). Initial transfections
were carried out in 24-well plates in order to establish optimal
knockdown conditions by titrating siRNA at 10, 25 and 50 nM.
Transfections for chromatin immunoprecipitation assays were
conducted at 50 nM final siRNA concentration.
Chromatin immunoprecipitation assay (ChIP)
MDA-MB-231 cells were treated with 30 mM adenosine
periodate methyltransferase inhibitor (AdOx, Sigma, St Louis,
MO, USA) and processed 48 hours later for ChIP using an
established protocol. Approximately 5610
6 cells were used per IP.
Cells were cross-linked with 1% formaldehyde at 37uC for 10
minutes, pelleted, washed, and cells lysed using SDS lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, one tablet
complete protease inhibitor cocktail per 50 ml) on ice for 10
minutes. Cells were sonicated on ice for 6 cycles to obtain an
average DNA length of 500 to 1200 bp. Lysate was clarified by
centrifugation at 4uC for 10 minutes at 14,000 rpm. Supernatant
was then diluted 10 fold in ChIP dilution buffer (0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0,
167 mM NaCl) and pre-cleared with a mixture of protein A/G
agarose (blocked previously with 1 mg/ml salmon sperm DNA
and 1 mg/ml BSA, Stratagene, La Jolla, CA, USA) at 4uC for
1 hour. Pre-cleared chromatin was incubated with 10 mgo f
antibody at 4uC overnight. Next day, 60 ml of 30% slurry of
blocked protein A/G agarose was added and complexes incubated
for 2 hours. Immune complexes were recovered by centrifugation
and washed once with low salt buffer (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl),
twice with high salt buffer (0.1% SDS, 1% Triton X-100 2 mM
EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl), once with
LiCl buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM
EDTA, 10 mM Tris-HCl, pH 8.0), and once with TE buffer.
Immune complexes were eluted twice with elution buffer (1%
SDS, 0.1 M NaHCO3) and incubating at room temperature for
15 minutes on a rotating wheel. Cross-links were reversed by
BRCA1 Methylation
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The next day, proteinase K (100 mg/ml final concentration) was
added and samples incubated at 55uC for 1 hour. Samples were
extracted with phenol:chloroform twice and ethanol precipitated
overnight. Pellets were then washed with 70% ethanol, dried,
resuspended in 50 ml of TE and assayed by PCR. Thirty-five
cycles of PCR were performed in 50 ml with 10 ml of immuno-
precipitated material, 0.1 mM of primers, 0.2 mM dNTPs, and 1
unit of Taq DNA polymerase. Finally, PCR products were
electrophoresed on 2% agarose gels and visualized by ethidium
bromide staining.
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